A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas.
Paolo Andrea Zucali,Alexia Bertuzzi,Hector Soto Parra,Elisabetta Campagnoli,Vittorio Quagliuolo,Armando Santoro +5 more
TL;DR: It is suggested that second/third-line therapy with dacarbazine leads to satisfactory disease control in refractory soft tissue sarcomas; its activity seems to be comparable with other treatments, such as high dose ifosfamide or ecteinascidin-743, but it has a better toxicity profile.
Journal ArticleDOI
Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy.
Luca Castagna,Stefania Bramanti,Monica Balzarotti,Barbara Sarina,Elisabetta Todisco,Antonella Anastasia,Massimo Magagnoli,Rita Mazza,Andrea Nozza,Laura Giordano,Marcello Rodari,Eva Rinifilo,Arturo Chiti,Armando Santoro +13 more
TL;DR: It is shown that interim PET can predict the outcome after high‐dose chemotherapy in HL patients, and was found to be more predictive than either negative or positive PET2.
Journal ArticleDOI
Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC)
Andrew X. Zhu,Olivier Rosmorduc,J. Evans,Paul Ross,Armando Santoro,Flair José Carrilho,MA LeBerre,Markus Jensen,Gerold Meinhardt,Y-K. Kang +9 more
TL;DR: Erlotinib, when added to sorafenib as standard of care in advanced HCC, did not prolong OS or TTP, and safety profiles were consistent with those of the individual agents.
Journal ArticleDOI
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry.
David J. Pinato,Meera Patel,Lorenza Scotti,Emeline Colomba,Saoirse Dolly,Angela Loizidou,John D. Chester,Uma Mukherjee,Alberto Zambelli,Alessia Dalla Pria,Juan Aguilar-Company,Mark Bower,Ramon Salazar,Alexia Bertuzzi,Joan Brunet,Matteo Lambertini,Marco Tagliamento,Anna Pous,Ailsa Sita-Lumsden,Krishnie Srikandarajah,Johann Colomba,Fanny Pommeret,Elia Seguí,Daniele Generali,Salvatore Grisanti,Paolo Pedrazzoli,Gianpiero Rizzo,Michela Libertini,Charlotte Moss,Joanne Evans,Beth Russell,Nadia Harbeck,Bruno Vincenzi,Federica Biello,Rossella Bertulli,Diego Ottaviani,Raquel Liñan,Sabrina Rossi,M Carmen Carmona-García,Carlo Tondini,Laura Fox,Alice Baggi,Vittoria Fotia,Alessandro Parisi,Giampero Porzio,Paola Queirolo,Claudia Andrea Cruz,Nadia Saoudi-Gonzalez,Eudald Felip,Ariadna Roqué Lloveras,Thomas Newsom-Davis,Rachel Sharkey,Elisa Roldán,Roxana Reyes,Federica Zoratto,Irina Earnshaw,Daniela Ferrante,Javier Marco-Hernández,Isabel Ruiz-Camps,Gianluca Gaidano,Andrea Patriarca,Riccardo Bruna,Anna Sureda,Clara Martinez-Vila,Ana Sanchez de Torre,Rossana Berardi,Raffaele Giusti,Francesca Mazzoni,Annalisa Guida,Lorenza Rimassa,Lorenzo Chiudinelli,Michela Franchi,Marco Krengli,Armando Santoro,Aleix Prat,Josep Tabernero,Mieke Van Hemelrijck,Nikolaos Diamantis,Alessandra Gennari,Alessio Cortellini,Alessio Cortellini +80 more
TL;DR: In this article, the severity and mortality from COVID-19 among patients with cancer have improved during the course of the SARS-CoV-2 pandemic in Europe.
Journal ArticleDOI
ABVD in the treatment of Hodgkin's disease.
TL;DR: Clinical results achieved at the Milan Cancer Institute in advanced Hodgkin's disease through successive randomized studies performed during the last two decades confirm the therapeutic activity of a regimen containing bleomycin and doxorubicin, and can be refined in the attempt to further decrease iatrogenic toxicity.